Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and - negative women

Journal of Infectious Diseases

Volumn 174, Issue 5, 1996, Pages 937-943

  Wideroff, L ^a   Schiffman, M H ^f   Hoover, R ^f   Tarone, R E ^f   Nonnenmacher, B ^b   Hubbert, N ^f   Kirnbauer, R ^c   Greer, C E ^d   Lorincz, A T ^f   Manos, M M ^e   Glass, A G ^f   Scott, D R ^f   Sherman, M E ^f   Buckland, J ^f   Lowy, D ^f   Schiller, J ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c Universitatsklinik fur Dermatologie   (Austria)

^d NOVARTIS PHARMA AG   (Switzerland)

^e DIVISION OF RESEARCH   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROCONVERSION; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; WART VIRUS;

EID: 19244363100     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.5.937     Document Type: Article

References (28)

1. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 1995; 64.
2. Daling JR, Sherman KJ. Relationship between human papillomavirus infection and tumors of anogenital sites other than cervix. IARC Sci Publ 1992:119:223-41.
3. Gravitt PE, Manos MM. Polymerase chain reaction-based methods for the detection of human papillomavirus DNA. IARC Sci Publ 1992; 119: 121-33.
4. EM de Villiers. Hybridization methods other than PCR: an update. IARC Sci Publ 1992;119:111-9.
5. Schiller JT, Roden RBS. Papillomavirus-like particles. Papillomavirus Rep 1995;6:121-8.
6. Dillner J. Antibody response to defined HPV epitopes in cervical neoplasia. Papillomaviras Rep 1994;5:35-41.
7. Galloway DA. Serological assays for the detection of HPV antibodies. IARC Sci Publ 1992;119:147-61.
8. Kimbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus types 16 LI and L1-L2 into virus-like particles. J Virol 1993;67:6929-36.
9. Kimbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillo-mavirus type 16. J Natl Cancer Inst 1994; 86:494-9.
10. Wideroff L, Schiffman MH, Nonnenmacher B, et al. Evaluation of serore-activity to HPV 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 1995; 172:1425-30.
11. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991;265:472-7.
12. Manos MM, Waldman J, Zhang TY, et al. Epidemiology and partial nucleotide sequence of four novel genital human papillomaviruses. J Infect Dis 1994; 170:1096-9.
13. Schiffman MH, Kiviat NB, Burk RD, et al. Accuracy and interlaboratory reliability of the hybrid capture test for human papillomavirus DNA. J Clin Microbiol 1995;33:545-50.
14. Thomas DG, Gart JJ. Improved and extended exact and asymptotic methods for the combination of 2X2 tables. Comput Biomed Res 1992;25: 75-84.
15. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993; 85:958-64.
16. Wilkstrom A, van Doornum GJJ, Quint WGV, Schiller JT, Dillner J. Identification of human papillomavirus seroconversions. J Gen Virol 1995;76:529-39.
17. Carter J, Koutsky LA, Wipf GC, et al. Development of anti-HPV capsid antibodies following incident HPV infection among a cohort of university women [abstract 7]. In: Program and abstracts of the 14th Interna-tional Papillomavirus Conference. Quebec: Université Lavai Faculté de Médecine, 1995.
18. Brinton LA. Oral contraceptives and cervical neoplasia. Contraception 1991;43:581-94.
19. Delgado-Rodriguez M, Sillero-Arenas M, Martin-Moreno JM, Galvez-Vargas R. Oral contraceptives and cancer of the cervix-uteri: a metaanalysjs. Acta Obstet Gynecol Scand 1992; 71:368-76.
20. Ley C, Bauer HM, Reingold A, et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst 1991;83: 991-1003.
21. Gloss B, Bernard HU, Seedorf K, KIock G. The upstream regulatory region of the human papillomavirus 16 contains an E2 protein independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones. EMBO J 1987;6:3735-43.
22. Mittal R, Pater A, Pater MM. Multiple human papillomavirus type 16 glucocorticoid response elements functional for transformation, transient expression, and DNA-protein interactions. J Virol 1993; 67:5656-9.
23. Mittal R, Tsutsumi K, Pater A, Pater MM. Human papillomavirus type 16 expression in cervical keratinocytes: role of progesterone and glucocorticoid hormones. Obstet Gynecol 1993; 81:5-12.
24. Chan WK, Klock G, Bernard HU. Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia. J Virol 1989; 63: 3261-9.
25. Mitrani-Rosenbaum S, Tsvielli R, Tur-Kaspa R. Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol 1989; 70:2227-32.
26. Hsu EM, McNicol PJ, Guijon FB, Paraskevas M. Quantification of HPV-16 E6-E7 transcription in cervical intraepithelial neoplasia by reverse transcriptase polymerase chain reaction. Int J Cancer 1993; 55:397-401.
27. Schneider A, Koutsky LA. Natural history and epidemiologic features of genital HPV infection. IARC Sci Publ 1992; 119:25-52.
28. Jackson ME, Campo MS. Cooperation between papillomavirus and chemical cofactors in oncogenesis. Crit Rev Oncog 1993;4:277-91.